All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial

Bristol Myers Squibb’s (BMS’s) Phase III trial of Zenbexus (iberdomide) has more than doubled progression-free survival (PFS) in patients with…
ArriVent’s stock plummets on Phase III NSCLC trial failure

ArriVent BioPharma’s stock has dropped 46% after a Phase III trial of its non-small cell lung cancer (NSCLC) candidate failed…
How advances in drug discovery are changing the path from research to clinical trials

Vini Jain, content and research team partner at Compound Vitality, explains how certain advancements in the preclinical stage are improving…
ViiV Healthcare’s Cabenuva beats daily oral ART in Phase IIIb trial

ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral antiretroviral therapy (ART) in adults…
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority

Vaxcyte’s stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its endpoints in a…

EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses

Regeneron Pharmaceuticals’ Phase II trial of its muscle-preservation drug for patients using glucagon-like peptide-1 receptor agonists (GLP-1RAs) has met its…
EASD 2026: Lilly’s amylin-tirzepatide combo beats its weight loss drug alone

Eli Lilly’s EloraTZP, a combination of eloralintide and tirzepatide, has proven more efficacious than tirzepatide alone in a Phase IIb…
Roadmap to recruitment: planning for patients at the start

Recruitment remains a significant challenge in the conduct of clinical trials worldwide. Low recruitment remains a key driver of trial…
Kyverna’s stiff-person syndrome trial shows one-year durability

Kyverna Therapeutics’ Phase III trial of a CAR-T therapy in stiff-person syndrome (SPS) has seen sustained benefit after one year.…
Roche targets Novartis on IgAN market after Phase III win

Roche is looking to take on Novartis after a Phase III trial of sefaxersen in primary IgA nephropathy (IgAN) met…